Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1996 Jun;70(6):3781–3787. doi: 10.1128/jvi.70.6.3781-3787.1996

A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge.

N L Davis 1, K W Brown 1, R E Johnston 1
PMCID: PMC190254  PMID: 8648713

Abstract

A candidate live-virus vaccine strain of Venezuelan equine encephalitis virus (VEE) was configured as a replication-competent vector for in vivo expression of heterologous immunogens. Three features of VEE recommend it for use as a vaccine vector. (i) Most human and animal populations are not already immune to VEE, so preexisting immunity to the vector would not limit expression of the heterologous antigen. (ii) VEE replicates first in local lymphoid tissue, a site favoring the induction of an effective immune response. (iii) Parenteral immunization of rodents and humans with live, attenuated VEE vaccines protects against mucosal challenge, suggesting that VEE vaccine vectors might be used successfully to protect against mucosal pathogens. Upon subcutaneous (s.c.) inoculation into the footpad of mice, a VEE vector containing the complete influenza virus hemagglutinin (HA) gene expressed HA in the draining lymph node and induced anti-HA immunoglobulin G (IgG) and IgA serum antibodies, the levels of which could be increased by s.c. booster inoculation. When immunized mice were challenged intranasally with a virulent strain of influenza virus, replication of challenge virus in their lungs was restricted, and they were completely protected from signs of disease. Significant reduction of influenza virus replication in the nasal epithelia of HA vector-immunized mice suggested an effective immunity at the mucosal surface. VEE vaccine vectors represent an alternative vaccination strategy when killed or subunit vaccines are ineffective or when the use of a live attenuated vaccine might be unsafe.

Full Text

The Full Text of this article is available as a PDF (732.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burke D. S., Ramsburg H. H., Edelman R. Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine. J Infect Dis. 1977 Sep;136(3):354–359. doi: 10.1093/infdis/136.3.354. [DOI] [PubMed] [Google Scholar]
  2. Burke K. L., Dunn G., Ferguson M., Minor P. D., Almond J. W. Antigen chimaeras of poliovirus as potential new vaccines. Nature. 1988 Mar 3;332(6159):81–82. doi: 10.1038/332081a0. [DOI] [PubMed] [Google Scholar]
  3. Charles P. C., Walters E., Margolis F., Johnston R. E. Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology. 1995 Apr 20;208(2):662–671. doi: 10.1006/viro.1995.1197. [DOI] [PubMed] [Google Scholar]
  4. Davis N. L., Brown K. W., Greenwald G. F., Zajac A. J., Zacny V. L., Smith J. F., Johnston R. E. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology. 1995 Sep 10;212(1):102–110. doi: 10.1006/viro.1995.1458. [DOI] [PubMed] [Google Scholar]
  5. Davis N. L., Powell N., Greenwald G. F., Willis L. V., Johnson B. J., Smith J. F., Johnston R. E. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology. 1991 Jul;183(1):20–31. doi: 10.1016/0042-6822(91)90114-q. [DOI] [PubMed] [Google Scholar]
  6. Davis N. L., Willis L. V., Smith J. F., Johnston R. E. In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology. 1989 Jul;171(1):189–204. doi: 10.1016/0042-6822(89)90526-6. [DOI] [PubMed] [Google Scholar]
  7. GLEISER C. A., GOCHENOUR W. S., Jr, BERGE T. O., TIGERTT W. D. The comparative pathology of experimental Venezuelan equine encephalomyelitis infection in different animal hosts. J Infect Dis. 1962 Jan-Feb;110:80–97. doi: 10.1093/infdis/110.1.80. [DOI] [PubMed] [Google Scholar]
  8. Grieder F. B., Davis N. L., Aronson J. F., Charles P. C., Sellon D. C., Suzuki K., Johnston R. E. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology. 1995 Feb 1;206(2):994–1006. doi: 10.1006/viro.1995.1022. [DOI] [PubMed] [Google Scholar]
  9. Hahn C. S., Hahn Y. S., Braciale T. J., Rice C. M. Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2679–2683. doi: 10.1073/pnas.89.7.2679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hughes S. H., Greenhouse J. J., Petropoulos C. J., Sutrave P. Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors. J Virol. 1987 Oct;61(10):3004–3012. doi: 10.1128/jvi.61.10.3004-3012.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jackson A. C., SenGupta S. K., Smith J. F. Pathogenesis of Venezuelan equine encephalitis virus infection in mice and hamsters. Vet Pathol. 1991 Sep;28(5):410–418. doi: 10.1177/030098589102800509. [DOI] [PubMed] [Google Scholar]
  12. Jahrling P. B., Stephenson E. H. Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters. J Clin Microbiol. 1984 Mar;19(3):429–431. doi: 10.1128/jcm.19.3.429-431.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kinney R. M., Esposito J. J., Mathews J. H., Johnson B. J., Roehrig J. T., Barrett A. D., Trent D. W. Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. J Virol. 1988 Dec;62(12):4697–4702. doi: 10.1128/jvi.62.12.4697-4702.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kunkel T. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A. 1985 Jan;82(2):488–492. doi: 10.1073/pnas.82.2.488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Levis R., Schlesinger S., Huang H. V. Promoter for Sindbis virus RNA-dependent subgenomic RNA transcription. J Virol. 1990 Apr;64(4):1726–1733. doi: 10.1128/jvi.64.4.1726-1733.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Li S., Polonis V., Isobe H., Zaghouani H., Guinea R., Moran T., Bona C., Palese P. Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J Virol. 1993 Nov;67(11):6659–6666. doi: 10.1128/jvi.67.11.6659-6666.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Liljeström P., Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) 1991 Dec;9(12):1356–1361. doi: 10.1038/nbt1291-1356. [DOI] [PubMed] [Google Scholar]
  18. Liljeström P., Lusa S., Huylebroeck D., Garoff H. In vitro mutagenesis of a full-length cDNA clone of Semliki Forest virus: the small 6,000-molecular-weight membrane protein modulates virus release. J Virol. 1991 Aug;65(8):4107–4113. doi: 10.1128/jvi.65.8.4107-4113.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. London S. D., Schmaljohn A. L., Dalrymple J. M., Rice C. M. Infectious enveloped RNA virus antigenic chimeras. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):207–211. doi: 10.1073/pnas.89.1.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lovett A. E., Hahn C. S., Rice C. M., Frey T. K., Wolinsky J. S. Rubella virus-specific cytotoxic T-lymphocyte responses: identification of the capsid as a target of major histocompatibility complex class I-restricted lysis and definition of two epitopes. J Virol. 1993 Oct;67(10):5849–5858. doi: 10.1128/jvi.67.10.5849-5858.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Moss B., Smith G. L., Gerin J. L., Purcell R. H. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature. 1984 Sep 6;311(5981):67–69. doi: 10.1038/311067a0. [DOI] [PubMed] [Google Scholar]
  22. Olmsted R. A., Meyer W. J., Johnston R. E. Characterization of Sindbis virus epitopes important for penetration in cell culture and pathogenesis in animals. Virology. 1986 Jan 30;148(2):245–254. doi: 10.1016/0042-6822(86)90322-3. [DOI] [PubMed] [Google Scholar]
  23. Piper R. C., Tai C., Slot J. W., Hahn C. S., Rice C. M., Huang H., James D. E. The efficient intracellular sequestration of the insulin-regulatable glucose transporter (GLUT-4) is conferred by the NH2 terminus. J Cell Biol. 1992 May;117(4):729–743. doi: 10.1083/jcb.117.4.729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Powers A. M., Olson K. E., Higgs S., Carlson J. O., Beaty B. J. Intracellular immunization of mosquito cells to LaCrosse virus using a recombinant Sindbis virus vector. Virus Res. 1994 Apr;32(1):57–67. doi: 10.1016/0168-1702(94)90061-2. [DOI] [PubMed] [Google Scholar]
  25. Ramphal R., Cogliano R. C., Shands J. W., Jr, Small P. A., Jr Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis. Infect Immun. 1979 Sep;25(3):992–997. doi: 10.1128/iai.25.3.992-997.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Staudt L. M., Gerhard W. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. I. Significant variation in repertoire expression between individual mice. J Exp Med. 1983 Feb 1;157(2):687–704. doi: 10.1084/jem.157.2.687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Strauss J. H., Strauss E. G. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev. 1994 Sep;58(3):491–562. doi: 10.1128/mr.58.3.491-562.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Xiong C., Levis R., Shen P., Schlesinger S., Rice C. M., Huang H. V. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science. 1989 Mar 3;243(4895):1188–1191. doi: 10.1126/science.2922607. [DOI] [PubMed] [Google Scholar]
  29. Yetter R. A., Lehrer S., Ramphal R., Small P. A., Jr Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect Immun. 1980 Aug;29(2):654–662. doi: 10.1128/iai.29.2.654-662.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Zhou X., Berglund P., Rhodes G., Parker S. E., Jondal M., Liljeström P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine. 1994 Dec;12(16):1510–1514. doi: 10.1016/0264-410x(94)90074-4. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES